share_log

Asensus Surgical Analyst Ratings

Benzinga Analyst Ratings ·  Feb 22, 2023 06:14
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/22/2023 252.98% HC Wainwright & Co. → $3 Reiterates → Buy
01/10/2023 252.98% HC Wainwright & Co. → $3 Reiterates → Buy
09/08/2022 76.49% Cantor Fitzgerald → $1.5 Initiates Coverage On → Overweight
08/10/2022 252.98% HC Wainwright & Co. $4 → $3 Maintains Buy
05/26/2021 370.64% HC Wainwright & Co. → $4 Initiates Coverage On → Buy

What is the target price for Asensus Surgical (ASXC)?

The latest price target for Asensus Surgical (AMEX: ASXC) was reported by HC Wainwright & Co. on February 22, 2023. The analyst firm set a price target for $3.00 expecting ASXC to rise to within 12 months (a possible 252.98% upside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Asensus Surgical (ASXC)?

The latest analyst rating for Asensus Surgical (AMEX: ASXC) was provided by HC Wainwright & Co., and Asensus Surgical reiterated their buy rating.

When is the next analyst rating going to be posted or updated for Asensus Surgical (ASXC)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Asensus Surgical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Asensus Surgical was filed on February 22, 2023 so you should expect the next rating to be made available sometime around February 22, 2024.

Is the Analyst Rating Asensus Surgical (ASXC) correct?

While ratings are subjective and will change, the latest Asensus Surgical (ASXC) rating was a reiterated with a price target of $0.00 to $3.00. The current price Asensus Surgical (ASXC) is trading at is $0.85, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment